You are here

ASH 2023

ASH: J&J, Sanofi square off in newly diagnosed multiple myeloma

Fierce Pharma

Wed, 12/13/23 - 09:45 am

Multiple Myeloma

ASH: Abecma’s survival data show why FDA wanted expert meeting on the Bristol Myers cell therapy

Fierce Pharma

Mon, 12/11/23 - 10:55 pm

Bristol Myers Squibb

ASH23: Pharma branding, Editas’ high bar and clinical trial diversity

BioPharma Dive

Mon, 12/11/23 - 10:52 pm

Editas Medicine

cliincal trials

ASH: Roche offers glimpse of Columvi-Polivy combo's early lymphoma data as phase 3 kicks off

Fierce Pharma

Mon, 12/11/23 - 10:50 pm

diffuse large B-cell lymphoma

ASH: As Novartis enters PNH market, AstraZeneca shows longer term effect of its latest contender

Fierce Biotech

Mon, 12/11/23 - 10:07 am

Legend Biotech to Showcase Leadership in Multiple Myeloma Treatment at the ASH 2023 Annual Meeting

BioSpace

Thu, 11/2/23 - 11:36 am

Multiple Myeloma